Standard BioTools: Strategic Realignment Impresses Major Investors - Insider Buying Totals Approximately $1.74 Million

Standard BioTools Inc. (LAB) presented its Q2 report on August 11. The company reported total revenue of $42.0 million and revenue from continuing operations of $21.8 million. A key milestone was the announced divestiture of SomaLogic to Illumina for up to $425 million in cash plus future royalties. This transaction is expected to close in the first half of 2026, providing the company with at least $550 million in cash. Michael Egholm, the President and CEO of Standard BioTools, emphasized that this transaction validates the company's business...